industry biotechnology founded 1992 1992 headquarters martinsried germany key people simon moroney founder and ceo gerald m ller chairman of the supervisory board products antibodies revenue 87.0 million 2010 1 operating income 9.8 million 2010 1 profit 9.2 million 2010 1 total assets 212.6 million end 2010 1 total equity 185.9 million end 2010 1 number of employees 460 end 2010 1 website www.morphosys.com morphosys ag is a german biotechnology company . it is involved in the development and research of antibodies . 2 tecdax has listed morphosys since 2004 . contents 1 technology 2 patent dispute with cambridge antibody technology 3 history 4 pipeline 5 references 6 external links technology edit morphosys generates human antibodies that contain 100 % human proteins . 3 the company has named this technology hucal human combinatorial antibody library and is an antibody production method based on phage display . patent dispute with cambridge antibody technology edit both morphosys and cambridge antibody technology based their therapeutic antibody discovery technologies on phage display . due to the significant cat patent estate the two came together from 1999 to 2002 in a number of patent disputes that were eventually settled . 4 timeline of disputes 1999 26 april morphosys announced that it has filed a lawsuit against cambridge antibody technology in the united states district court for the district of columbia . the lawsuit sought a declaration that morphosys does not infringe cat s recently issued us patent 5 885 793 covering certain methods of producing human antibodies . the suit also sought to have the cat patent declared invalid . 5 1999 14 october morphosys announced a favourable outcome to its opposition against the uk medical research council s winter ii patent which was exclusively licensed to cambridge antibody technology . the outcome was based on a decision announced by the european patent office epo on an opposition morphosys lodged against the patent . the decision required changes to the language of the key claim in the patent thereby significantly narrowing the scope of protection . 6 2001 20 june morphosys confirmed that cambridge antibody technology together with the medical research council and the scripps research institute had initiated a lawsuit at the united states district court for the southern district of california in san diego alleging infringement of cat s winter ii us patent . the winter ii patent covers certain antibody expression libraries and methods of generating such libraries and was granted in the usa on june 19 2001 u.s. patent no. 6 248 516 . 7 2001 25 june morphosys announced that a lawsuit initiated by cambridge antibody technology together with the medical research council and the scripps research institute alleging infringement of their winter ii us patent no. 6 248 516 had been dismissed by the united states district court for the southern district of california in san diego . the lawsuit was filed by cat on june 19 2001 and was dismissed by the court on friday june 22 2001 for lack of jurisdiction and improper venue . morphosys has now filed an action for declaratory judgment in the u.s. district court for the district of columbia in washington d.c. 8 2001 19 august morphosys announced that a court in san diego has granted its motion to dismiss a second attempt by cambridge antibody technology together with the medical research council the scripps research institute and stratagene to bring a suit alleging infringement of their winter ii us patent no. 6 248 516 . in late june the court dismissed cat s earlier filed suit against morphosys on the same patent . prior to cat s second filing morphosys filed a suit in a district court in washington dc seeking a declaration of non infringement and invalidity of the winter ii patent . 9 2001 19 august morphosys announced that the district court in washington dc issued a preliminary ruling in its favour in the dispute with cambridge antibody technology concerning the griffiths patent u.s. patent 5 885 793 . the ruling followed a march 2001 trial at which the jury was unable to reach a verdict on the validity of the patent or whether morphosys infringed it . the preliminary ruling issued on august 17 states that morphosys should prevail on the issue of infringement pending further briefings or proceedings . 10 2001 20 september morphosys confirmed that cambridge antibody technology together with medical research council scripps research institute and stratagene had initiated a lawsuit at the united states district court of washington d.c. alleging infringement of two of cat s recently granted huse lerner winter patents in the u.s. the two huse lerner winter patents subject to those proceedings allegedly covering certain antibody expression libraries and were granted in the u.s.a. on september 19 2001 u.s. patent nos. 6 291 158 and 6 291 161 . the lawsuit alleges that morphosys infringes three claims found in the two patents . 11 2002 28 january morphosys announced that on january 24 2002 the u.s. district court in washington d.c. had denied cambridge antibody technology s motion to dismiss or transfer a suit filed by morphosys seeking declaratory judgement for non infringement and invalidity of the u.s. winter ii patent no. 6 248 516 . as a result the winter ii patent case in the u.s. will now proceed as a morphosys action for declaratory judgement in the washington d.c. district court . the decision relating to the winter ii lawsuit involves a separate proceeding from that relating to the favorable ruling morphosys received on december 21 2001 from the same court concerning the u.s. griffiths patent no. 5 885 793 . in the griffiths case the court stated its intent to enter partial summary judgement against cat in favor of morphosys on cat s claim of infringement unless a genuine issue as to any material fact remains for trial . 12 2002 3 november morphosys ag announced that on march 8 2002 the district court in washington dc issued a final ruling in its favor in the dispute with cambridge antibody technology concerning the griffiths patent u.s. patent 5 885 793 . according to the court ruling morphosys application of its proprietary hucal antibody libraries does not infringe the claims of the griffiths patent thereby giving morphosys full freedom to operate with regard to the patent . 13 2002 23 december morphosys ag and cambridge antibody technology announced that they had agreed to settle all patent disputes between the two companies . the settlement agreement covered morphosys past present and future use and commercialisation of all versions of its hucal libraries and included the most recent development at that time hucal gold and related to all patents in the ongoing disputes between the two companies . this included litigation in the united states regarding cat s griffiths mccafferty winter ii and winter lerner huse patents as well as oppositions launched by morphosys at the european patent office against cat s winter ii and mccafferty patents . the companies agreed to terms under which morphosys will be free to develop and commercialise its hucal technologies . cat undertook not to sue morphosys in relation to present hucal gold libraries and all future derivatives thereof . in addition morphosys received a licence to the cat patent estate in respect of previous hucal libraries . cat received an annual payment of 1 million over the next five years . it was to also receive other financial consideration from morphosys activities related to its hucal gold libraries for a defined period of time . cat would receive milestone and royalty payments under the licence for products developed using previous hucal libraries . in addition cat would receive an equity stake of 588 160 ordinary shares in morphosys under the licence agreement . morphosys retained the option to buy out its obligations to cat for a pre defined fixed amount at any time during the duration of the agreement . 14 history edit in january 2013 bio rad purchased abd serotec a division of morphosys ag that sold antibodies . 15 pipeline edit morphosys has numerous candidates in its clinical development pipeline . 16 as of october 2012 its most advanced drug candidate is mor103 a fully human hucal antibody directed against gm csf granulocyte macrophage colony stimulating factor developed in the area of inflammatory diseases i.e. rheumatoid arthritis . 17 references edit a b c d e f annual report 2010 pdf . morphosys . retrieved 27 march 2010 . morphosys strengthens patent position on its core hucal technology in europe . retrieved 2008 03 24 . http www.morphosys.com en technologies advantages of human antibodies 130.html http www.morphosys.com en company history 85.html http www.morphosys.com en news investors press release 209.html http www.morphosys.com en news investors press release 208.html http www.morphosys.com en news investors press release 167.html http www.morphosys.com en news investors press release 166.html http www.morphosys.com en news investors press release 164.html http www.morphosys.com en news investors press release 163.html http www.morphosys.com en news investors press release 162.html http www.morphosys.com en news investors press release 135.html http www.morphosys.com en news investors press release 134.html http www.morphosys.com en news investors press release 132.html bio rad acquires abd serotec from morphosys . 17 december 2012 . http www.morphosys.com en therapeutic antibodies overview 446.html http www.morphosys.com en therapeutic antibodies proprietary therapeutic product pipeline 317.html external links edit official website abd serotec now bio rad antibodies v t e tecdax companies of germany updated 18.03.2013 adva optical networking aixtron bb biotech bechtle cancom ag carl zeiss meditec dialog semiconductor dr gerwerk drillisch euromicron evotec freenet ag jenoptik kontron lpkf laser & electronics morphosys nordex se pfeiffer vacuum psi ag qiagen qsc ag sartorius ag sma solar technology software ag stratec biomedical systems s ss microtec telef nica germany united internet wirecard xing retrieved from https en.wikipedia.org w index.php title morphosys & oldid 735239978 categories biotechnology companies of germany navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages deutschfran ais edit links this page was last modified on 19 august 2016 at 12 45 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view